Related Experiment Video

Updated: Jan 22, 2026

Whole-body PET/MRI of Pediatric Patients: The Details That Matter
10:02

Whole-body PET/MRI of Pediatric Patients: The Details That Matter

Published on: December 19, 2017

15.2K

Lipomatous Tumors in Pediatric Patients: A Retrospective Analysis of 50 cases

Mine Özşen1, Ulviye Yalçinkaya, Zeynep Yazici

  • 1Department of Pathology, Erzurum Regional Training and Research Hospital, ERZURUM, TURKEY.

Turk Patoloji Dergisi
|July 9, 2019
PubMed

Insights

Pediatric lipomatous tumors are rare but diverse, with lipoma and lipoblastoma being most common. Close monitoring is crucial due to potential recurrence and growth, even after treatment.

Area of Science:

  • Pediatric Oncology
  • Surgical Pathology
  • Soft Tissue Tumors

Background:

  • Lipomatous tumors are common in adults but rare in pediatric patients, representing less than 10% of soft tissue lesions.
  • Limited literature exists on the prevalence and incidence of pediatric lipomatous tumors, necessitating further research.

Purpose of the Study:

  • To present a series of pediatric lipomatous tumors including lipoma, neural fibrolipoma, lipoblastoma, atypical lipomatous tumor, myxoid liposarcoma, and pleomorphic liposarcoma.
  • To evaluate the clinicopathological characteristics of these pediatric tumors and compare them with existing literature.

Main Methods:

  • Retrospective evaluation of pediatric lipomatous tumor cases diagnosed between 2002 and 2018.
  • Screening of pathological archives for relevant cases.

Main Results:

  • A total of 50 pediatric lipomatous tumor cases were identified.
  • Histopathological examination revealed lipoma (52%), lipoblastoma (38%), atypical lipomatous tumor (4%), myxoid liposarcoma (4%), and pleomorphic liposarcoma (2%).
  • The age distribution ranged from 1 to 204 months, with a near-equal gender distribution (48% female, 52% male).

Conclusions:

  • Pediatric lipomatous tumors are uncommon but exhibit diverse histopathological types.
  • These tumors can grow large and cause symptoms through compression, and local recurrences are possible, requiring vigilant follow-up.
  • Further studies are needed to establish definitive data on the prevalence and incidence of pediatric lipomatous tumors.
Abstract

More Related Videos

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions07:39

Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions

Published on: November 17, 2021

3.9K
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

850

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
214
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
269
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
198
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
260
Patient-centered Care01:13

Patient-centered Care

Patient-centered care involves delivering care beyond inpatient hospitalization. Reflective practice can enhance a patient-centered approach. Reflective practice is a process of reasoning that considers all aspects of the present situation, including practicalities, learning from personal practice, and consideration of patient needs. Patients appreciate care decisions made while considering their input. Involving the patient in their care provides the patient with a sense of contribution rather...
2.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K